Articles From: Industry Groundbreaking Energy Focus 500D Series LED Tube Lamp Offers 150 Lumens Per Watt of Light to Dr. Reddy’s Announces the Launch of Valganciclovir Tablets, USP


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982483001&sourceType=1 http://media3.marketwire.com/logos/20140922-922enb-logo.jpg CALGARY, ALBERTA --
Sign-up for Enbridge Announces 33% Dividend Increase, Financial Restructuring Plans, Revised Payout Policy and 2015 Adjusted Earnings Guidance investment picks
CINCINNATI , Dec.
Sign-up for Scripps and Journal receive FCC approval investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977287001&sourceType=1 http://media3.marketwire.com/logos/20130909-909stn.jpg EDMONTON, ALBERTA and NEW YORK, NEW YORK --
Sign-up for Stantec announces third quarter 2014 results and dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160756&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Eos Petro Announces Extension of Tender Offer for Any and All Outstanding Shares of Dune Energy investment picks
http://media.marketwire.com/attachments/201007/9697_Lithia-Logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155119&ProfileId=051205&sourceType=1 MEDFORD, OR --
Sign-up for Lithia Motors Reports Adjusted EPS of $1.32 for the Third Quarter of 2014, an Increase of 17% Over the Prior Year investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0979211001&sourceType=1 http://www.ccnmatthews.com/logos/20111129-peyto_200.jpg CALGARY, ALBERTA --
Sign-up for Peyto Exploration & Development Corp. Confirms Dividends for December 15, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978623001&sourceType=1 http://media3.marketwire.com/logos/20141110-centuryiron200.jpg TORONTO, CANADA --
Sign-up for Century Reports Completion of 2014 Sunny Lake DSO Drilling Program and Positive Initial Assay Results investment picks
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D® 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014.
Sign-up for Dr. Reddy’s Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets investment picks
LEUVEN, Belgium, Nov.
Sign-up for Materialise Software Makes it Easier Than Ever to Print on Concept Laser Metal 3D Printers investment picks
Actions Will Sharpen Focus on Operations and Guest Experience While Reducing Costs Plan Includes Senior Leadership Changes, Streamlining of Support and Operations Functions, and Closure of Corporate Aviation Department ORLANDO, Fla.
Sign-up for Darden Announces Leadership Changes And Strategic Actions investment picks
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company’s 400-patient Phase 3 registration trial (“Rocket 1”) of Rhopressa TM , a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Sign-up for Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial (“Rocket 1”) of Rhopressa™, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma investment picks
MB Financial, Inc. (the “Company”), (Nasdaq: MBFI) announced today that its Board of Directors has declared a cash dividend of $0.14 per share, payable on December 31, 2014 to holders of record of the Company’s common stock as of December 15, 2014.
Sign-up for MB Financial, Inc. Approves Dividend investment picks
EINDHOVEN, Netherlands and LAS VEGAS, Jan.
Sign-up for 81 Percent of Americans Admit Privacy Concerns With the Internet of Things investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0987203001&sourceType=1 http://www.ccnmatthews.com/logos/20090812-bplo.JPG CALGARY, ALBERTA --
Sign-up for BlackPearl Revises 2015 Capital Spending Plans Due to Lower Crude Oil Prices investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G028631-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/16/11G028631/20130207-eca_200-473944305185.jpg CALGARY, AB--(Marketwired - December 16, 2014) - Encana (TSX: ECA) (NYSE: ECA) today announced a highly focused 2015 capital program of between $2.7 billion and $2.9 billion, with approximately 80 percent directed to four of its highest margin growth plays; the Montney, Duvernay, Eagle Ford and Permian.
Sign-up for Encana Focuses 2015 Capital Program on Four Strategic Growth Assets investment picks
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE ® (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). The VALCYTE ® (Valganciclovir) tablets brand had U.S. sales of approximately $440 Million MAT for the most recent twelve months ending in October 2014 according to IMS Health*. Dr.
Sign-up for Dr. Reddy’s Announces the Launch of Valganciclovir Tablets, USP investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Industry Groundbreaking Energy Focus 500D Series LED Tube Lamp Offers 150 Lumens Per Watt of Light to Dr. Reddy’s Announces the Launch of Valganciclovir Tablets, USP
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent